New stock news | InnoCare Pharma's Hong Kong stock IPO prospectus failed.

According to Zhilu Finance APP, the Hong Kong IPO prospectus submitted by Immvira Bioscience Inc. (referred to as Yino Micro Medicine) on January 14, 2026, expired after 6 months on July 14, 2026. Citigroup and China International Capital Corporation (CICC) acted as its joint sponsors.